Read a Q-and-A with Jasmine May, a fifth-year student in the Medical Scientist Training Program, who studies the pathophysiology of glioblastoma.
The first drug using spherical nucleic acids to be systemically given to humans has been developed by Northwestern University scientists and approved by the Food and Drug Administration as an investigational new drug for an early-stage clinical trial in the deadly brain cancer glioblastoma multiforme.
A study published in Cancer Cell revealed the mechanism by which a gene fusion called ETO2-GLIS2 promotes the development of an aggressive form of acute megakaryoblastic leukemia.
A combination of ultrasound and cystoscopy is the most cost-effective approach to detecting cancer in patients who show microscopic amounts of blood in their urine, according to a JAMA Internal Medicine study.
A study sheds new light on the molecular foundations of human acral lentiginous melanoma, a rare sun-shielded melanoma.
OncoSET, the flagship clinical and research program of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, combines oncology with genomic sequencing to provide cutting-edge cancer care personalized for each patient.
Women who underwent autologous breast reconstruction following a mastectomy reported greater psychosocial and sexual well-being than those who chose implant-based reconstruction, according to a study published in the Journal of Clinical Oncology.
Targeting a molecule called B7-H4 may lead to the development of new therapies that boost the immune system’s ability to fight cancer, according to a review published in the journal Immunological Reviews.
Northwestern Medicine scientists have developed a novel testing platform to assess, in real time, the efficacy of nanomaterials in regulating gene expression.
Northwestern medicine scientist have shown how a medical device that delivers alternating electrical fields in addition to traditional chemotherapy can improve survival for patients with glioblastoma.